REward SYSTem in Autism Spectrum Disorder and Addictive Disorder (RESYSTAA)

July 28, 2023 updated by: University Hospital, Tours

Stimuli Sociaux et Non-sociaux du système de récompense : Une étude en IRM Chez Des Sujets Avec Trouble du Spectre de l'Autisme et Des Sujets Avec un Trouble Addictif à l'Alimentation. - RESYSTAA

An MRI Study in Subjects with Autism Spectrum Disorder and Subjects with Food Addictive Disorder compared to healthy volunteers.

Study Overview

Status

Recruiting

Detailed Description

An MRI Study in Subjects with Autism Spectrum Disorder and Subjects with Food Addictive Disorder compared to healthy volunteers, where pathophysiology common to both disorders, based on a dysfunction of the reward system. The project we propose aims to explore the neural networks underlying these alterations in patients suffering from autism or addictive disorder.

Study Type

Interventional

Enrollment (Estimated)

78

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Tours, France, 37044
        • Recruiting
        • Center-Val de Loire Region Autism Resource Center
        • Contact:
        • Principal Investigator:
          • Frédéric BRIEND, PhD
        • Sub-Investigator:
          • Marianne LATINUS, PhD
        • Sub-Investigator:
          • Laurent BARANTIN, PhD
        • Sub-Investigator:
          • Emmanuelle HOUY-DURAND, MD-PhD
      • Tours, France, 37044
        • Recruiting
        • University Addictology Service, Liaison Team and Addictology Care
        • Contact:
        • Sub-Investigator:
          • Paul BRUNAULT, MD-PhD
      • Tours, France, 37044
        • Recruiting
        • University Hospital, Medical Imaging Service
        • Contact:
        • Sub-Investigator:
          • Jean-Philippe COTTIER, MD-PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Arm A ˗ Concerning ASD patients: Adult carrying the diagnosis of ASD (DSM-5, ADOS, ADI-R criteria)

Arm B ˗ Concerning FAD patients: Adult diagnosed with FA presenting with food addiction (DSM-5, YFAS 2.0, BES >= 18 criteria).

Arm C ˗ Concerning healthy volunteers : Adult with no neurological and psychiatric history , absence of progressive somatic pathologies or with vital risk.

For all participants:

  • Age greater than or equal to 18 years old
  • Without intellectual delay (IQ > 70).
  • Able to understand and apply the instruction when an active task is proposed, according to the estimate of the investigator.
  • Free, express, informed and written consent of the participant.
  • Participant affiliated to a social security scheme

Exclusion Criteria:

  • Neuromotor disorders.
  • Visual disturbances not corrected or incompatible with MRI.
  • Known epilepsy.
  • Current substance use disorder with emotional distress/significant impact on functional outcome
  • Rare genetic syndrome.
  • Contraindications to MRI (other than body circumference)
  • For women of childbearing age: negative urine or blood pregnancy test
  • Person subject to a measure of judicial protection (safeguard of justice, curatorship, guardianship or family authorization)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Autism Spectrum Disorder
Characterized by two main diagnostic criteria: a socio-emotional deficit via a defect in communication and social reciprocity, and a behavioral deficit which manifests itself in repetitive behavioral patterns (stereotypes), restricted interests and/or activities.
an fMRI measurement of the BOLD physiological signal for sensory responses
Other Names:
  • Functionnal MRI
These tests, through videos with a social or non-social content (human presence or absence on the stereoscopic projection), will allow us to study two types of sensorialities (visual and interoceptive). Thus, it will be possible to obtain inter- and exteroceptive profiles of the participants, a direct reflection of the processing of the internal bodily sensations of the body.
Other Names:
  • Electro Encephalography
Active Comparator: Food Addictive Disorders
Characterized by regroup substance use disorders and behavioral addictions, are characterized in particular by the repeated occurrence of compulsive behavior and impaired social functioning
an fMRI measurement of the BOLD physiological signal for sensory responses
Other Names:
  • Functionnal MRI
These tests, through videos with a social or non-social content (human presence or absence on the stereoscopic projection), will allow us to study two types of sensorialities (visual and interoceptive). Thus, it will be possible to obtain inter- and exteroceptive profiles of the participants, a direct reflection of the processing of the internal bodily sensations of the body.
Other Names:
  • Electro Encephalography
Placebo Comparator: Healthy volonteers
Adult without neurological and psychiatric history, absence of progressive somatic pathologies or with vital risk.
an fMRI measurement of the BOLD physiological signal for sensory responses
Other Names:
  • Functionnal MRI
These tests, through videos with a social or non-social content (human presence or absence on the stereoscopic projection), will allow us to study two types of sensorialities (visual and interoceptive). Thus, it will be possible to obtain inter- and exteroceptive profiles of the participants, a direct reflection of the processing of the internal bodily sensations of the body.
Other Names:
  • Electro Encephalography

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood Oxygene Level Dependent (BOLD) MRI signal
Time Frame: At inclusion
Measurement in fMRI of the BOLD signal for each condition (interest, addiction, social) will be carried out in order to highlight the possible alterations of the reward system, in particular at the level of the striatum in terms of cerebral activation for each of the groups of subjects. (FAD, ASD and HV).
At inclusion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tolerance to an MRI examination for FAD with overweight or obesity
Time Frame: At inclusion
For the tolerance to an MRI examination for FAD with overweight or obesity: feedback on their experience in MRI.
At inclusion
Regulation of sensory, an fMRI measurement of the BOLD physiological signal for sensory responses (sensory block) in terms of brain activation in patients
Time Frame: At inclusion
Regulation of sensory, an fMRI measurement of the BOLD physiological signal for sensory responses (sensory block) in terms of brain activation in patients with FAD compared to ASD subjects and healthy volunteers.
At inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Frédéric BRIEND, PhD, University Hospital,Tours -INSERM U1253 iBrain

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 27, 2023

Primary Completion (Estimated)

July 27, 2026

Study Completion (Estimated)

January 27, 2027

Study Registration Dates

First Submitted

May 20, 2022

First Submitted That Met QC Criteria

May 20, 2022

First Posted (Actual)

May 25, 2022

Study Record Updates

Last Update Posted (Actual)

August 1, 2023

Last Update Submitted That Met QC Criteria

July 28, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • DR220016-RESYSTAA
  • 2022-A01098-35 (Registry Identifier: ID RCB-ANSM)
  • 22-87 (Registry Identifier: CPP SUD-MED IV)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autism Spectrum Disorder

Clinical Trials on MRI

3
Subscribe